摘要：Datamonitor analysis recognises 18 biological brands that are expected to drive sales within the biopharma sector. The group includes 12 recombinant DNA proteins and six antibodies which are forecast to generate sales of US$29.0bn and US$13.2bn by 2008, respectively. Haematology, oncology and AIID (arthritis, inflammation and immune disorders) will drive blockbuster sales, reaching US$11.2bn, US$9.7bn and US$8.3bn by 2008, respectively.
